Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- When we try to hide from China we can get whacked upside the head, Jim Cramer told his Mad Money viewers Tuesday. The pain was excruciating for many stocks today, including some big U.S. names.
Look at Action Alerts PLUS holding Apple's (AAPL) - Get Report three million-phone sales miss in the second quarter. It coincided with the peak of the Shanghai composite in mid-June and the freefall through the end of the month. The stock was down 3.21% at today's close and off almost 15% from its record high in April.
So Apple is not for the squeamish right now. There may be too many analysts recommending it and institutional investors may be overweighted in it. And, of course, Apple isn't an island. The supplier companies riding its coattails -- including Skyworks Solutions (SWKS) - Get Report, NXP Semiconductors (NXPI) - Get Report, Avago Technologies (AVGO) - Get Report and Qorvo (QRVO) - Get Report -- have been pounded relentlessly, Cramer said.
CVS (CVS) - Get Reportreported earnings today, showing pharmacy results that rocked, Cramer said. But results in other segments were poor now that the company doesn't sell tobacco. Pessimistic market reaction to news out of CVS Health and even Disney (DIS) - Get Report -- down over 6% in late trading -- suggests the best places to hide in today's market are in stocks with the highest risk -- such as Netflix (NFLX) - Get Report, up nearly 8% at the close.
Executive Decision: Dusty McCoy
In the "Executive Decision" segment, Cramer welcomed Brunswick (BC) - Get Report CEO Dusty McCoy, whose company's stock has been relatively muted this year and tumbled after reporting strong second-quarter earnings. Its brands include Attwood, Boston Whaler, Quicksilver, Mercury Racing and LifeFitness. Last week, BC reported earnings of $1.05 per share, beating estimates by 3 cents.
McCoy said that there's been a trend of the stock going down after second-quarter earnings are announced, and then seeing a bounceback after third-quarter numbers. That's because most people see it as a primarily marine company.
The used boat market has really come under a lot of supply pressure ever since the Great Recession, which is why McCoy is "comfortable" about the new boat market coming back. He has a positive outlook for the second half of the year.
McCoy also discussed a new initiative that finds the company focused on the 75% of the population who don't exercise regularly but want to be well and healthy. Brunswick is launching new business centered around walking treadmills and standing desks.
In the "Homework" segment Cramer said it was time to address some of the biotech questions from viewers that stumped him earlier this year.
Cramer said Uniqure (QURE) - Get Report "seems like a good stock to me." Uniqure is a leading gene therapy developer whose lead drug has been approved in Europe for treating patients with LPLD, a rare genetic disease that can lead to pancreatitis. Shares are up 78% for the year having maintained a huge jump after meeting significant milestones earlier this year.
La Jolla Pharmaceuticals (LJPC) - Get Report is a small biotech focused on attacking life-threatening orphan diseases. Its signature drug treats patients with catecholamine-resistant hypertension, which can cause blood pressure to plummet to dangerous levels. Phase III results are expected by the end of next year. LJPC is up nearly 60% year to date, and more than 800% over the past two years. Cramer thinks most of the upside is already baked-in here.
As for Pacira Pharmaceuticals (PCRX) - Get Report, it's all about its pain-management products, particularly post-surgical pain. It has a proprietary delivery technology -- DepoFoam -- that encapsulates addictive drugs to release them over time, minimizing some addictive effects. PCRX is down 30% year-over-year. The stock is certainly cheaper but with no real catalyst and potentially serious legal overhang, Cramer sees no reason to own it.
Cramer discussed blood-treatment company Karyopharm Therapeutics (KPTI) - Get Report. Its stock is in a speculative developmental stage with its lead product Selinexor, and has experienced a more-than 40% drop year to date after a secondary offering in January. It's a good entry point for investors who are prepared for what might be a rocky road ahead.
Progenics Pharmaceuticals (PGNX) - Get Report announced today it's entering a licensing agreement with Johns Hopkins for its anti-constipation drug for patients taking opioid painkillers. Cramer likes the stock but recommends waiting for a bigger pullback.
Finally, Array BioPharma (ARRY) - Get Report, another anti-cancer biotech. It has six phase II studies in the mix right now. The stock is down 30% over the last six weeks, but Cramer sees it as a speculative bargain at this level, as long as you're willing to bear some pain and volatility.
Executive Decision: Robert Abernathy
In his second "Executive Decision" segment, Cramer sat down with Robert Abernathy, chairman and CEO of Halyard Health (HYH) , the medical supply company spun off from Kimberley Clark (KMB) - Get Report last year and an Action Alerts PLUS holding. The stock was down 11.8% today on disappointing results and guidance cut on fiscal year 2015.
Abernathy said it had been a tough quarter. The company's medical device business performed very well last quarter, while its surgical and infection prevention segment struggled. Those divisions make up 31% and 69% of sales, respectively.
Abernathy said he plans to continue to separate the company from KMB and expand its shift toward medical devices. Innovation and a stronger second half could allow Halyard to improve in the second half of 2015, Abernathy said.
Cramer said he screwed up on this one because Abernathy has missed twice.
No Huddle Offense
Cramer has been pondering recent breakups, specifically health care outfit Baxter International (BAX) - Get Report, and print company RR Donnelley (RRD) - Get Report, which plans to split off valuable assets.
Today, Shire (SHPG) - Get Report made a $30 billion hostile bid for blood-franchise drugmaker Baxalta (BXLT) , which Baxter spun off on July 1. Baxalta soared, and once the deal closes its owners will be up 18%.
Meanwhile, RRD announced plans to split into three companies. Cramer said it makes a lot of sense because the financial communications services, printing business and multi-channel communications management company didn't belong under one roof. Cramer said the print services business is an especially good opportunity for RRD to make strategic acquisitions and consolidate the industry.
Cramer said BAX and RRD are proof that breaking up doesn't always have to be hard to do. It can be easy, and lucrative, over time.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL, HYH and PYPL.